The EHMT1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of HeLa cells with targeted disruption of the EHMT1 gene. This loss-of-function model is generated by Cas9-mediated gene editing, resulting in a heterogeneous pool of cells harboring EHMT1 gene disruptions. Unlike single-cell clones, this polyclonal format offers a population-level knockout system suitable for studying EHMT1-dependent epigenetic mechanisms without clonal expansion artifacts. The product serves as a versatile tool for investigators examining the role of EHMT1-catalyzed histone methylation in gene regulation and disease.
The HeLa cell line, derived from a human cervical adenocarcinoma, is immortalized and retains integrated HPV18 sequences, driving aggressive proliferation and an aneuploid genome. As a widely used epithelial model, HeLa cells are permissive to genetic manipulation and have been instrumental in dissecting signaling pathways and chromatin biology. Their rapid growth and stable epigenetic landscape make them an ideal host for evaluating the functional consequences of EHMT1 loss in a cancer-cell background.
EHMT1 is a histone methyltransferase that functions within the EHMT1-G9a-WIZ complex to catalyze mono- and dimethylation of histone H3 at lysine 9 (H3K9me1/me2). These marks recruit heterochromatin protein 1 (HP1??/HP1??) and facilitate HDAC-mediated chromatin compaction, leading to transcriptional repression. EHMT1 activity is stimulated by the E2F1 transcription factor downstream of DNA damage responses and Wnt/??-catenin signaling. It directly silences tumor suppressor genes such as CDH1, CDKN1A, and PTEN, as well as the pro-apoptotic gene BCL2L11, while also modulating NF-??B target genes. EHMT1 cooperates with cofactors including CtBP, DNMT3A, and NPAC/GLYR1, and its catalytic function is interdependent with its paralog EHMT2 (G9a).
In the HeLa cell context, EHMT1 knockout disrupts the silencing of key growth-regulatory and apoptosis-related genes, offering a model to probe epigenetic contributions to cervical cancer progression. HeLa??s HPV18-positive status and aneuploidy create a unique epigenetic environment where the interplay between viral oncoproteins and host methylation machinery can be investigated. Loss of EHMT1-mediated H3K9 methylation may relieve repression of p53 effectors and CDH1, potentially altering cell cycle, migration, and drug responses. Thus, this polyclonal pool enables dissection of EHMT1??s role in maintaining the transformed phenotype and its crosstalk with p53 and Wnt pathways.
Researchers can employ this model in a broad spectrum of epigenetic studies, including validation of EHMT1 as a therapeutic target in cancer. It is well-suited for chromatin-based assays such as western blotting for global H3K9me1/me2 levels, ChIP-qPCR on promoters of CDH1 and CDKN1A, and immunofluorescence to assess HP1 foci formation. RNA-seq analysis can identify derepressed gene networks. Functional assays such as proliferation, apoptosis, and drug sensitivity testing with EHMT inhibitors like UNC0642 are enabled. This polyclonal knockout cell population also supports disease modeling for Kleefstra syndrome-related neurodevelopmental pathways. For ordering information or technical inquiries, please contact Ascent Research.
